Table 3 Characteristics of included studies
Authors, year of publication, Country | Study design, period | Newcastle–Ottawa score | Sample size | Age(years) | Sex | Risk factors found for the mortality of HBV-ACLF | Measures of associations | Selection criteria for HBV-ACLF |
|---|---|---|---|---|---|---|---|---|
Zhang, X., et al. 2022 China [24] | Cohort 2013–2021 | 8 points | n = 163 | 46 (37–56) | Male = 149 | - | HR | APASL |
Female = 14 | ||||||||
Yang, J., et al. 2022 China [25] | Cohort 2019–2020 | 8 points | n = 180 | NA | Male = 19 | Monocytes | OR | APASL |
Female = 161 | ||||||||
Weng, W.Z., et al. 2022 China [15] | Cohort 2010–2018 | 7 points | n = 2166 | 45 (37–54) | Male = 1914 | Cirrhosis, SBP, HE, HRS | HR | CMASL |
Female = 252 | ||||||||
Wang, L., et al. 2022 China [26] | Cohort 2014–2018 | 7 points | n = 1177 | 45.06 (10.57) | Male = 124 | Cirrhosis, HE | OR | APASL |
Female = 1153 | ||||||||
Lin, L., et al. 2022 China [27] | Case control 2015–2021 | 8 points | n = 116 | NA | Male = 98 | HE, SBP, INR | OR | APASL |
Female = 18 | ||||||||
Xue, R., et al. 2021 China [28] | Cohort 2014–2018 | 7 points | n = 171 | 45.17 (12.49) | Male = 151 | HE, Monocytes | OR | APASL |
Female = 20 | ||||||||
Xiao, L.L., et al. 2021 China [14] | Cohort 2008–2015 | 6 points | n = 1973 | NA | Male = 1641 | INR | OR | APASL |
Female = 332 | ||||||||
Xiao, L., et al. 2021 China [29] | Cohort 2018–2020 | 8 points | n = 175 | NA | Male = 146 | INR, HE grade | OR | APASL |
Female = 29 | ||||||||
Sun, J., et al. 2021 China [30] | Cohort 2013–2019 | 8 points | n = 494 | 45 (37–55) | Male = 421 | HE, INR, HE grade | HR | APASL |
Female = 73 | ||||||||
Hu, H., et al. 2021 China [31] | Cohort 2017–2020 | 8 points | n = 96 | NA | Male = 79 | INR | OR | CMASL |
Female = 17 | ||||||||
Zhai, X.R., et al. 2020 China [13] | Cohort 2015–2017 | 7 points | n = 289 | NA | Male = 236 | INR, HE | HR | EASL |
Female = 53 | ||||||||
Jia, L., et al. 2020 China [12] | Case control 2013–2015 | 7 points | n = 171 | 45.1 (12.3) | Male = 152 | Cirrhosis, Monocytes, INR, HE, HRS | HR | APASL |
Female = 19 | ||||||||
Yi, Z.Q., et al. 2015 China [32] | Cohort 2008–2011 | 6 points | n = 392 | NA | Male = 323 | HE, INR | OR | APASL |
Female = 69 | ||||||||
Qin, G., et al. 2014 China [33] | Case control 2003–2007 | 7 points | n = 234 | NA | Male = 180 | INR, Cirrhosis, HE, HRS, SBP | HR | APASL |
Female = 54 | ||||||||
Hou, Y., et al. 2020 China [34] | Cohort 2008–2016 | 7 points | n = 684 | 43.9 (11.6) | Male = 582 | Hyponatremia, SBP, HE, HRS, INR | OR | APASL |
Female = 102 | ||||||||
Lu, J., et al. 2019 China [35] | Case control 2015–2017 | 6 points | n = 54 | 46.72 (12.26) | Male = 48 | HRS, HE, SBP | OR | APASL |
Female = 6 | ||||||||
Li, T.P., et al. 2019 China [36] | Case control 2017–2018 | 8 points | n = 106 | NA | Male = 87 | - | OR | APASL |
Female = 19 | ||||||||
Shi, X., et al. 2016 China [37] | Cohort 2010–2015 | 6 points | n = 1167 | NA | Male = 996 | HE | OR | CMASL |
Female = 171 | ||||||||
Zhang, G.L., et al. 2016 China [38] | Cohort 2009–2010 | 6 points | n = 65 | 41.52 (1.47) | Male = 62 | - | HR | APASL |
Female = 3 | ||||||||
Gao, F., et al. 2017 China [39] | Cohort 2003–2013 | 8 points | n = 573 | 43.5 (11.5) | Male = 478 | Hyponatremia, SBP, HE, HRS, INR | HR | APASL |
Female = 95 | ||||||||
Liu, L., et al. 2018 China [40] | Cohort 2009–2016 | 7 points | n = 355 | NA | Male = 290 | SBP | OR | APASL |
Female = 65 | ||||||||
Li, X., et al. 2017 China [41] | Cohort 2000–2015 | 7 points | n = 758 | NA | Male = 643 | INR | HR | APASL |
Female = 115 |